Efetividade a longo prazo da lisdexanfetamina para o tratamento de transtorno do déficit de atenção e hiperatividade e transtorno de compulsão alimentar
Vigilância Sanitária em Debate · 05.05.2026 · 1-10
DOI: 10.22239/2317-269x.02484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vigilância Sanitária em Debate, online erschienen am 05.05.2026. Verfasst von Maíra Catharina Ramos und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Lisdexamfetamine (LDX) is a medication indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, the medication is rapidly absorbed by the gastrointestinal tract and converted into D-amphetamine covalently bound to the natural amino acid L-lysine, responsible for the drug’s activity.
Objective
To evaluate the long-term effectiveness of Lisdexamfetamine for treating Attention Deficit Hyperactivity Disorder and Binge Eating Disorder.
Method
A search was conducted in PubMed, Embase, Web of Science, and Cochrane using descriptors and their respective synonyms to identify the long-term efficacy and safety of LDX in individuals with ADHD and BED. Interventional and controlled group studies with a follow-up period of more than 5 weeks were included.
Results
30 studies were included. Regarding the population, the effects of LDX were investigated in individuals aged 5-55 years, with the longest follow-up being 108 weeks. Overall, the literature indicates a significant reduction in symptoms within the first 5-6 weeks of treatment, stabilizing in the following weeks. For ADHD, studies up to 108 weeks reported mean reductions of –25.8 points on the ADHD-RS-IV (95% CI –27.0 to –24.5), improvement in CGI-I ratings from 42.3% to 89.1%, and maintenance-of-response rates above 75% in adults after 12 months. For BED, studies with up to 52 weeks of follow-up showed that 89.8% of participants experienced clinical improvement on the CGI-I, with significant reductions in weekly binge-eating days (least-squares mean differences up to –1.66; p < 0.001) and a mean improvement of –1.95 points on the EDE-Q.
Conclusions
The findings suggest that LDX shows promising long-term results for both health conditions. However, healthcare professional follow-up is necessary due to the drug’s adverse events.
Zitieren
APA
Ramos, M. C., Pereira, V. C., & Elias, F. T. S. (2026). Efetividade a longo prazo da lisdexanfetamina para o tratamento de transtorno do déficit de atenção e hiperatividade e transtorno de compulsão alimentar. Vigilância Sanitária em Debate, 1-10. https://doi.org/10.22239/2317-269x.02484
Vancouver
Ramos MC, Pereira VC, Elias FTS. Efetividade a longo prazo da lisdexanfetamina para o tratamento de transtorno do déficit de atenção e hiperatividade e transtorno de compulsão alimentar. Vigilância Sanitária em Debate. 2026:1-10. doi:10.22239/2317-269x.02484
BibTeX
@article{Ramos2026,
author = {Ramos, Maíra Catharina and Pereira, Viviane Cássia and Elias, Flávia Tavares Silva},
title = {Efetividade a longo prazo da lisdexanfetamina para o tratamento de transtorno do déficit de atenção e hiperatividade e transtorno de compulsão alimentar},
journal = {Vigilância Sanitária em Debate},
year = {2026},
pages = {1--10},
doi = {10.22239/2317-269x.02484}
}
EUVIMED